Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
Open Access
- 6 December 2022
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (2) , 465-476
Abstract
Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO. Methods This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months. Results In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate. Conclusion Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance.Keywords
Funding Information
- Novartis Vietnam Company Limited
This publication has 26 references indexed in Scilit:
- Secukinumab survival and long‐term efficacy in patients with plaque psoriasis: real‐life data from a tertiary hospital in GreeceJournal of the European Academy of Dermatology and Venereology, 2018
- Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observationExpert Opinion on Biological Therapy, 2018
- Long‐term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single‐center experienceThe Journal of Dermatology, 2017
- Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of the European Academy of Dermatology and Venereology, 2016
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2015
- PsoriasisThe Lancet, 2015
- Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims databaseBMJ Open, 2015
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic TherapyArchives of Dermatology, 2012
- Epidemiological Study of Psoriasis in the National Health Insurance Database in TaiwanActa Dermato-Venereologica, 2009